ACT Capital Partners, L.P.’s Sagimet Biosciences SGMT Stock Holding History

ACT Capital Partners, L.P.’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$593K	Buy	+60,000	New	+$551K	0.39%	31

Other funds holding SGMT

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Kestra Advisory Services Austin, Texas $35.1B AUM 20.13% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

ACT Capital Partners, L.P.'s SGMT Position: Q3 2026 in Review

ACT Capital Partners, L.P. opened a new position in Sagimet Biosciences (SGMT) in Q3 2026: 60,000 shares worth $593K. The stake represents 0.39% of the portfolio and ranks #31 among its holdings.

34 funds tracked by Wall St. Rank hold SGMT as of Q3 2026.

ACT Capital Partners, L.P. held 60,000 shares of Sagimet Biosciences worth $593K as of Q3 2026.
Sagimet Biosciences was a new ACT Capital Partners, L.P. position in Q3 2026.
Sagimet Biosciences made up 0.39% of ACT Capital Partners, L.P.'s portfolio in Q3 2026, its #31 holding.
34 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2026.

Based on ACT Capital Partners, L.P.'s 13F filing for Q3 2026, filed 6 Nov 2026.